Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience.

ABSTRACT:

Background

Precision oncology uses molecular profiling of tumors to identify biomarker-tailored therapies for patients in the hope of improving outcomes. Typically, only a minority of patients receives evaluable matched treatment. This study explored the reasons for attrition on a precision medicine trial.

Materials and methods

Study participants were 190 adult patients who consented to the I-PREDICT (Investigation of molecular Profile-Related Evidence Determining Individualized Cancer Therapy) trial. Patients had metastatic and/or unresectable incurable malignancies. Patients who were not evaluable were analyzed.

Results

Of consented patients, 44% were not evaluable. Men were twice as likely to be not evaluable as women. Prominently, 45% of patients who were not eval

SUBMITTER: Bohan SS 

PROVIDER: S-EPMC7648352 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature